Upstream / Downstream


Explore pathways related to this product.

Important Ordering Details

Custom Ordering Details: This product is assembled upon order. Please allow up to three weeks for your product to be processed

Pricing & Additional Information

To learn more about our Blocking Peptides, including pricing, please answer a few questions.

Pricing & Additional Information  


Find answers on our FAQs page.


Visit PhosphoSitePlus®

PTM information and tools available.


Immunohistochemical analysis of paraffin-embedded human tonsil using LEF1 (C12A5) Rabbit mAb #2230 in the presence of control peptide (left) or LEF1 Blocking Peptide (right).

Learn more about how we get our images

Product Description

This peptide is used to block LEF1 (C12A5) Rabbit mAb #2230 reactivity in immunohistochemistry protocols.

Quality Control

The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry. The peptide blocks LEF1 (C12A5) Rabbit mAb #2230 by immunohistochemistry.

Product Usage Information

Use as a blocking reagent to evaluate the specificity of antibody reactivity in immunohistochemistry protocols. For immunohistochemistry, add twice the volume of peptide as volume of antibody used in 100 µl total volume. Incubate for a minimum of 30 minutes prior to adding the entire volume to the slide. Recommended antibody dilutions can be found on the relevant product data sheet.

Storage: Supplied in 20 mM potassium phosphate (pH 7.0), 50 mM NaCl, 0.1 mM EDTA, 1 mg/ml BSA and 5% glycerol. Store at –20°C.

LEF1 and TCF are members of the high mobility group (HMG) DNA binding protein family of transcription factors that consists of the following: Lymphoid Enhancer Factor 1 (LEF1), T Cell Factor 1 (TCF1), TCF3, and TCF4 (1). LEF1 and TCF1 were originally identified as important factors regulating early lymphoid development (2) and act downstream in Wnt signaling. LEF1 and TCF bind to Wnt response elements to provide docking sites for β-catenin, which translocates to the nucleus to promote the transcription of target genes upon activation of Wnt signaling (3). LEF1 and TCF are dynamically expressed during development and aberrant activation of the Wnt signaling pathway is involved in many types of cancers including colon cancer (4,5).

1.  Waterman, M.L. (2004) Cancer Metastasis Rev 23, 41-52.

2.  Schilham, M.W. and Clevers, H. (1998) Semin Immunol 10, 127-32.

3.  Brantjes, H. et al. (2002) Biol Chem 383, 255-61.

4.  Reya, T. and Clevers, H. (2005) Nature 434, 843-50.

5.  Logan, C.Y. and Nusse, R. (2004) Annu Rev Cell Dev Biol 20, 781-810.

Entrez-Gene Id 51176
Swiss-Prot Acc. Q9UJU2

For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

LEF1 Blocking Peptide